Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
Same author

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL.

Blood·2026
Same author

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials.

BMJ oncology·2026
Same author

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.

bioRxiv : the preprint server for biology·2026
Same author

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies.

Transplantation and cellular therapy·2025
Same author

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Jun 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab resistance.

Andrew R Rezvani1, David G Maloney

  • 1Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, Seattle, WA 98109, USA. arezvani@fhcrc.org

Best Practice & Research. Clinical Haematology
|June 11, 2011
PubMed
Summary

Rituximab resistance in follicular lymphoma is complex, involving tumor cells and the immune system. Understanding these mechanisms is key to improving anti-CD20 antibody therapy for non-Hodgkin lymphoma.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Rituximab is a standard treatment for follicular non-Hodgkin lymphoma.
  • Mechanisms of rituximab resistance are not fully understood.
  • Resistance may involve tumor cell-intrinsic factors or the host immune environment.

Purpose of the Study:

  • To explore rituximab's mechanisms of action.
  • To review the incidence and mechanisms of rituximab resistance.
  • To discuss novel strategies to overcome resistance.

Main Methods:

  • Review of existing literature on rituximab efficacy and resistance.
  • Exploration of immunological and cellular mechanisms.
  • Discussion of potential therapeutic modulations.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jun 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Main Results:

  • Rituximab's efficacy is partly dependent on immune effector functions.
  • Resistance mechanisms can be multifactorial, involving tumor and host components.
  • Novel approaches target antibody, tumor cell, and immune environment.

Conclusions:

  • Further research into rituximab resistance is crucial for enhancing anti-CD20 therapy.
  • Understanding resistance can optimize monoclonal antibody therapies broadly.
  • Improving rituximab efficacy requires a comprehensive approach.